Why the study?
In-stent restenosis and stent thrombosis are major concerns when choosing a coronary stent, prompting evaluation of the long-term clinical outcomes of the Yukon Choice Flex sirolimus-eluting stent.
Does the Yukon Choice Flex sirolimus-eluting stent provide favorable safety and efficacy outcomes in patients undergoing PCI predominantly for acute coronary syndrome?
Does the Yukon Choice Flex sirolimus-eluting stent provide favorable safety and efficacy outcomes in patients undergoing PCI predominantly for acute coronary syndrome?
The Yukon Choice Flex sirolimus-eluting stent demonstrated a favorable safety and efficacy profile with low rates of cardiac death and stent thrombosis at 3 years in a predominantly ACS population in India.
Answers are grounded in this paper and cite their sources.
Supports favorable real-world profile in ACS PCI; leaves open need for randomized confirmation.
In-stent restenosis and stent thrombosis are the major concerns while choosing a coronary stent. This single-centre, retrospective study evaluated the one and three-year clinical outcomes following implantation of Yukon Choice Flex (YCF) sirolimus-eluting stent. A total of 168 consecutive patients with 217 lesions underwent stenting with YCF stent. The presentation was with acute coronary syndrome in 158 (94%) patients. At 3 years, 9 (5.3%) patients died due to cardiac cause. Myocardial infarction, and definite stent thrombosis occurred in 10 (6%) and 4 (2.4%) patients respectively. Redo stenting and coronary artery bypass surgery was performed in 3 (1.8%) and 1 (0.6%) patient respectively. The use of YCF sirolimus eluting stent was associated with a favourable safety and efficacy profile at one and three-years of follow-up in a high-risk population.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: